More than 2500 Australians commence kidney replacement therapy each year and many more die of kidney failure as a result of kidney fibrosis. TGF-β, a growth factor causing kidney fibrosis, is also anti-inflammatory. Our project aims to prove that targeting a downstream messenger (β-catenin) of TGF-β will prevent kidney fibrosis while leaving TGF-β’s anti-inflammatory actions untouched. A successful outcome will lead to a novel cure for preventing kidney fibrosis and fibrosis of other organs.

Supervisor: Dr. Guoping Zheng, guoping.zheng@sydney.edu.au